Gene Editing

Eli Lilly will acquire Verve Therapeutics, a clinical-stage company focused on gene editing therapies for cardiovascular disease. The deal, valued at approximately $1 billion, aims to advance Verve’s one-time treatment approach targeting genes linked to heart disease. Lilly plans to leverage its expertise in cardiometabolic diseases and gene medicines to develop Verve’s pipeline, including VERVE-102.